I ” intent- to- treat ” (ITT) populationen, opnåede 70% af patienterne i abacavirgruppen, sammenlignet med 69% af patienterne i zidovudingruppen, et virologisk respons af plasma HIV- 1 RNA ≤ 50 kopier/ ml ved uge 48 (point estimate for behandlingsforskel:
In the intent-to-treat (ITT) population, 70% of patients in the abacavir group, compared to 69% of patients in the zidovudine group, achieved a virologic response of plasma HIV-1 RNA ≤ 50 copies/ ml by Week 48 (point estimate for treatment difference: